Barnala Geographical Location Map
Mile Stones Crossed 1986 – IOLCP Established 1991 – Commenced Acetic Acid Production 1996 – Commissioned Ethyl Acetate Plant 1999 – Commenced Acetic Anhydride Production 2000 – Commissioned Ibuprofen Plant 2006 – Commissioned Power Cogeneration
Product Range Active Pharmaceutical Ingredients Ibuprofen Proton Pump Inhibitors (PPI’s)(Proposed) Chemical Products Acetic Acid Ethyl Acetate Acetic Anhydride MCA & Acetyl Chloride IBB
Capacity By Product Capacity ( TPA ) Acetic Acid Ethyl Acetate Acetic Anhydride Ibuprofen Products
Revenues USD 20 mln USD 36 mln USD 48 mln USD 75 mln USD 70 mln Years
Operating Profit USD 1.8 mln USD 3.8mln USD 3.9 mln USD 7.7 mln USD 7.2 mln Years
Net Profit After Tax USD 0.53 mln USD 1.51 mln USD 1.57 mln USD 2.57 mln USD 2.64 mln Years
Revenue Distribution By Product (%) Products
Export Sales USD 0.41 mln USD 2.70mln USD 4.79 min USD 10.4 min USD 9.16mln Years
GROWTH - Projects Under Implementation • Recently increased Ibuprofen capacity from 1800 TPA to 3600 TPA . • Currently implementing projects for Capacity Expansions, Forward & Backward Integration & Power Cogeneration, involving a capital expenditure of Rs 256 Crores (approx USD 53.3 million). • Commencing a new project for the production of PPI’s i.e. Rabiprazole, Omeprazole, Pantoprazole Esomeprazole and Lansoprazole in Jan 2010 at a cost of Rs 100 Crores ( approx USD 20.83 million).
Co-generation Expanding captive power cogeneration capacity to 17 MW, from 4 MW currently Present captive energy generation include Steam and Power Generation
Monochloroacetic Acid & Acetyl ChlorideProcess Flow Acetic Anhydride Acetic Acid HCl Acetic Acid (By Product) Chlorine Gas HCl (By Product) Acetyl Chloride MCA
Uses of Iso-Butyl Benzene IBB PLANT SPENTGAS IBB HIGH HYDRO CARBON LOW HYDRO CARBON POTASIUM CARBONATE THERMO PACK MARKET ACETIC ANHY DRIDE CAPTIVE CONSUMP TION CO- GEN ACETIC ANHY DRIDE ACETIC ANHY DRIDE MARKET THERMO PACK MARKET THE END PACK REUSE IN IBB PROCESS CO- GEN
Projected Capacity Fiscal Year 2011-12 ALL OF THESE PROJECTS WILL HAVE TO BE FINANCED FROM INTERNAL ACCRUALS AND TERM DEBT WITHOUT FURTHER DILUTION IN EQUITY. THIS WILL RESULT IN SIGNIFICANT GROWTH IN PROFITABILITY AND EARNINGS PER SHARE
Global Market Presence The various international markets catered till date include: 1.BANGLADESH 15.IRAN 29.SPAIN 43.ITALY 2.EGYPT 16.VEITNAM 30.PHILIPPINES 44.MAURITIUS 3.UGANDA 17.KUWAIT 31.CHILE 45.CHILE 4.SYRIA 18.GERMAN 32.ZIMBABWE 46.TAIWAN 5.AUSTRALIA 19.COLOMBIA 33.URUGUAY 47.TASMANIA 6.DUBAI 20.SINGAPORE 34.GHANA 48.OMAN 7.PAKISTAN 21.HONG KONG 35.TURKEY 49.COLOMBIA 8.THAILAND 22.MALAWI 36.CHINA 50.SOUTH AMERICA 9.MALAYSIA 23.BRAZIL 37.CONGO 51.YEMEN 10.BOLIVIA 24.SOUTH KOREA 38.SUDAN 11.MEXICO 25.PERU 39.NIGERIA 12.VENEZUELA 26.GUATEMALA 40.KENYA 13.ALGERIA 27.NEPAL 41.NEW ZEALAND 14.LATAVIA 28.DENMARK 42.SRI LANKA
Non-Steroidal Anti – Inflammatory Drug (NSAID) Reduces Hormones Causing Inflammation & Pain in Body Usage in Treatment of Variety of Ailments Grades Available : - IP / BP /USP / EP /JP - Micronized - Dexibuprofen - DC ( Directly compressible ) Ibuprofen
Ibuprofen - Market Share Domestic Market Global Market Indian Market 8000 MT per Annum Global Market 25,000 MT per Annum
Acetic Acid • Acetic Acid or Ethanoic Acid Commonly Known as Vinegar • Sour Taste & Pungent Smell • Widely used as Chemical Reagent & Industrial Chemical • Derivatives application almost in all fields
Applications & End Usage –Acetic Acid *IOLCP is Entering into the Manufacturing of MCA with the Capacity of 7200 TPA.
Acetic Acid – Market Share Domestic Market Global Market Indian Market 4,50,000 MT per Annum Global Market 92,00,000 MT per Annum
Ethyl Acetate • Ethyl Acetate or Ethyl Ethanoate – Fragrant, Colorless Liquid • Diverse Industrial Application as Solvent • Usage as Synthetic Fruit Essence • Flavor in Pharmaceuticals • Coextractant of Camphor, Fats, Oils & Antibiotics • Ability to replace Aromatic Solvents like Toulene, Xylene & Methyl Isobutyl Ketone.
Ethyl Acetate - Market Share Domestic Market Global Market Indian Market 1,90,000 MT per Annum Global Market 14,00,000 MT per Annum
Acetic Anhydride • Ethanoic Anhydride or Acid Anhydride • Declared As “Controlled Substance” under the Narcotics Drugs & Psychotropic Substances (NDPS) Act 1985 by Narcotics Control Bureau, India • Usage in Pharmaceutical, Agrochemical, Dyes & Pigments, Cellulose Acetate Production
Applications & End Usage-Acetic Anhydride *IOLCP is installing the Manufacturing Plant of Acetyl Chloride with the Capacity of 5200 TPA.
Acetic Anhydride - Market Share Domestic Market Global Market Indian Market 55,000 MT per Annum Global Market 2,00,000 MT per Annum
1.Producing MCA without using hydrogenation. 2. MCA Plant is equipped with bubble cap graphite distillation Column instead of packed column. 3. Plant is equipped with Scrubbing System to take care of Environment Aspects. 4. In the Plant 900 critical parameters controlled by DCS for maintaining product quality and quantity Upcoming ProjectsMCA & Acetyl Chloride
5.Plant is based on forward and backward integration of existing products. 6.Acetyl Chloride is manufactured with HCL root instead of other root to reduce its cost and byproduct. 7.Process Parameters are designed using Simulation Software “CHEMCAD” Supplied by Chemstations USA. 8.Equipped with Teflon coated pipe and fitting to minimize maintenance problem. Contd..
1.IBB Plant is equipped with Pneumatic transfer System instead of pumps to save power. 2.In the Plant 1400 Critical parameters controlled by DCS to maintain product quality and Yield. 3.In the Plant Air Compressors are equipped with Variable Frequency toget Energy Efficiency. 4. IBB Plant is the Backward integration of existing product of IOLCP. Iso Butyl Benzene
Manufacturing & Consumption(India) ( MCA, IBB, Acetyl Chloride )
The company has planned for installation of new manufacturing facilities of PPIs- i.e. Rabiprazole, Omeprazole, Esomeprazole, Lansoprazole & Pantoprazole . Rabiprazole is used to treat conditions where the stomach produces too much acid, including ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. The total amount of Capital Expenditure will be about Rs 100 Crores ( approx USD 20.83 million). The Project of Rabiprazole is planned to be implemented from 2009-10. Upcoming Diversification PlansAnti-ulcerants- Proton Pump Inhibitors (PPI’s)